IgE-Sensitized Mast Cells: A Programmable Platform for Antigen-Triggered Oncolytic Virotherapy

Abstract

In a recent study published in Cell, Xu et al. developed a “programmable” delivery system using IgE-sensitized mast cells as antigen-triggerable carriers for oncolytic viruses (OVs). This strategy achieves precise, on-demand viral release within the tumor microenvironment (TME) while simultaneously harnessing intrinsic degranulation and chemotactic capacities to transform mast cells from passive vehicles into potent immune “accelerators” that amplify antitumor immunity [1] (Figure 1).

Oncolytic viruses have emerged as a promising platform that bridges direct tumor lysis and in situ vaccine effects. However, their clinical translation has been persistently constrained by two major bottlenecks. First, following systemic administration, OVs are readily cleared from circulation, exhibit heterogeneous intratumoral distribution, and are substantially neutralized by pre-existing or treatment-induced antiviral antibodies [2, 3]. Second, even when OVs successfully reach tumors, the immunosuppressive TME often limits dendritic cell (DC) activation and effector T-cell expansion, resulting in an insufficient immune cascade [4, 5]. Against this backdrop, the selection of mast cells as delivery vehicles by Xu et al. [1] is far from incidental. Mast cells express high levels of FcεRI on their surface and rapidly undergo degranulation upon IgE crosslinking, releasing cytokines and chemokines that reshape the local immune niche—an intrinsic mechanism ideally suited for spatiotemporally controlled release and immune recruitment amplification.

The study first established and characterized IgE-sensitized mast cells (IgE-MCs). Structurally, scanning electron microscopy revealed corresponding changes in cell morphology and surface features following sensitization and activation. Functionally, antigen stimulation induced robust secretion of TNF-α, IL-6, CCL2, and CCL3, and pharmacological inhibitor pretreatment confirmed the controllability of this activation pathway. Furthermore, through live-cell imaging and confocal z-stack analyses, the authors visualized dynamic interactions between IgE-MCs and tumor cells, as well as granule-associated behaviors. In tumor tissues, alterations in the abundance and enrichment of CD117⁺FcεRI⁺ mast cells were observed. Notably, single-cell transcriptomic profiling and clustering of intratumoral CD45⁺ immune cells demonstrated markedly enhanced immune infiltration following IgE-MC treatment, with gene expression patterns consistent with CD8⁺ T-cell migration. Among these, the CCL3 axis was specifically identified through gene-editing and migration assays as a key driver of activated CD8⁺ T-cell chemotaxis and intratumoral accumulation.

Building upon this foundation, Xu et al. developed the OV@IgE-MC delivery system. Confocal and transmission electron microscopy clearly showed that OVs could be loaded into mast cells and associated with granule structures. Importantly, antigen triggering induced mast-cell degranulation accompanied by enhanced viral release, resulting in an antigen-gated release profile. In vitro infection assays demonstrated that OV@IgE-MCs infected tumor cells more efficiently than free virus or nonsensitized carriers. Even in the presence of OV-neutralizing antibodies, this delivery platform retained a substantial advantage, suggesting a degree of immune shielding and delivery protection. Consistently, pharmacological stabilization of mast cells using agents such as cromolyn suppressed degranulation and reduced intratumoral viral genome copy numbers, mechanistically supporting a degranulation–release–infection causal chain.

In a subcutaneous B16F10-OVA tumor model, OV@IgE-MCs conferred significantly superior tumor suppression and survival benefits compared with all control groups, including OVs alone, MCs, IgE-MCs, or OV@MCs. At the tissue level, stronger indicators of viral infection (e.g., EGFP signals) and immune remodeling were observed. Flow-cytometric analyses further revealed increased activation and maturation of intratumoral DCs (CD80⁺CD86⁺), an elevated proportion of CD103⁺ DCs, enhanced CD8⁺ T-cell infiltration, and a reduction in immunosuppressive populations such as regulatory T cells. Cytokine profiling of tumor tissues also indicated amplified local immune activation. Integrated with single-cell T-cell transcriptomic data, the authors demonstrated that OV@IgE-MC treatment induced more pronounced transcriptional reprogramming of CD8⁺ T cells than OV monotherapy, enriching pathways associated with effector function, migration, and immune activation. These findings fill a critical gap in the oncolysis–antigen release–DC activation–T-cell effector cascade.

To assess applicability in metastatic settings, the study employed lung metastasis and pulmonary colonization models, in which OV@IgE-MCs significantly reduced in vivo bioluminescent signals and the number of surface lung metastases. These results were corroborated by H&E staining and quantitative analyses. Peripheral immune monitoring revealed increased proportions of CD3⁺ and CD8⁺ T cells, while immunofluorescence of lung lesions showed enhanced infiltration of both CD8⁺ T cells and mast cells. Together, these findings indicate that the strategy exerts not only local antitumor effects but also measurable systemic immune responses.

Of particular translational relevance, Xu et al. [1] extended their validation to humanized patient-derived xenograft models. Using a humanized immune background and OV@IgE-sensitized human mast cells (OV@IgE-hMCs), the authors observed suppressed tumor growth, reduced endpoint tumor weight, and relatively stable body weight. Tumor tissues exhibited increased infiltration of CD3⁺ and CD8⁺ T cells, with significantly elevated IFN-γ⁺ CD8⁺ and GZMB⁺ CD8⁺ effector populations. This advancement moves the concept from murine syngeneic models toward systems that more closely approximate clinical complexity, providing a practical foundation for subsequent development addressing safety, dosing, and manufacturing scalability.

Overall, this work redefines mast cells as an engineerable “immuno-delivery unit.” IgE sensitization provides a specific triggering switch, degranulation offers a rapid release conduit, chemokine networks function as immune recruitment amplifiers, and OV cargo delivers tumor lysis and in situ vaccination effects. Compared to conventional cell-based platforms—such as macrophages, which primarily leverage tumor-homing patterns, or T cells, which often focus on active targeting—the mast cell-based approach offers a distinct kinetic advantage. By utilizing the explosive nature of the degranulation process, this strategy bypasses the slow, passive release associated with other carriers, providing a “burst-on-demand” mechanism that is uniquely coupled with the host′s allergic signaling machinery. This integrated delivery–release–immune remodeling framework is particularly well suited to overcoming core barriers faced by oncolytic virotherapy, including suboptimal biodistribution, immune clearance, and insufficient immune priming.

Nonetheless, several critical scientific and engineering challenges must be systematically addressed before clinical translation. First, the safety window and controllability of IgE-mediated triggering across diverse patient immune backgrounds require careful definition, particularly with respect to antigen design, route optimization, and the incorporation of reversible safety-valve mechanisms to minimize the risk of hypersensitivity reactions. Crucially, the practical feasibility of clinical implementation remains constrained by the challenges of obtaining and expanding sufficient quantities of autologous mast cells. Unlike more abundant circulating leukocytes, the scarcity of primary mast cells in peripheral blood necessitates highly efficient isolation and robust ex vivo expansion protocols to meet therapeutic dosages, posing a significant hurdle for large-scale application. Second, the pronounced heterogeneity of tumor antigens may affect the consistency and predictability of IgE-mediated activation, suggesting that future iterations may benefit from exogenous controllable antigens, universal trigger modules, or combination with complementary immunomodulatory strategies to enhance robustness across heterogeneous patient populations. Central to this robustness is a deeper understanding of the intricate crosstalk between engineered mast cells and other components of the TME, such as T cells, macrophages, and fibroblasts. Deciphering how these interactions modulate the local immune landscape will be pivotal in ensuring sustained therapeutic efficacy. Third, as an engineered cell-based therapeutic product, issues related to manufacturing workflows, viral loading efficiency, in vivo stability, and batch-to-batch consistency must be standardized and scaled in compliance with regulatory requirements, posing substantial challenges for process development and quality control. Despite these hurdles, this platform holds significant promise for broad clinical application across a variety of solid tumors, potentially serving as a versatile modular system for precision immunotherapy.

The study establishes a highly distinctive translational strategy: by harnessing programmable immune-cell biology, it reconceptualizes the traditional “delivery problem” as a precisely triggerable and immunologically amplifiable therapeutic process. In this model, delivery itself becomes an integral component of the antitumor immune cascade. This conceptual framework not only provides a new entry point for oncolytic virotherapy but also offers important insights into how drugs, biologics, and multimodal immunotherapies may achieve spatiotemporally precise release and synergistic amplification in vivo.

Lin Chen: investigation, writing original – draft, drawing. Yu-Xuan Jin: writing original draft. Jin-Lyu Sun: conceptualization, project administration, writing – review and editing. All authors have read and approved the final manuscript.

The authors have nothing to report.

The authors declare no conflicts of interest.

No data sets were generated or analyzed during the current study.